Mechanotransduction Failure During Surgical Wound Remodeling: Pathophysiology, Clinical Implications, and Management

Abstract

Mechanotransduction—the process by which cells convert mechanical stimuli into biochemical signals—is fundamental to successful wound healing and surgical wound remodeling. Its failure can result in impaired tissue regeneration, chronic non-healing wounds, and suboptimal surgical outcomes. This review synthesizes current understanding of mechanotransduction failure during surgical wound remodeling, emphasizing pathophysiological mechanisms, clinical presentation, diagnostic strategies, management approaches, and emerging therapies. The article integrates recent PubMed-indexed evidence and guideline-based recommendations, providing clinicians with up-to-date, mechanistically-informed insights to optimize patient care.

Introduction

Surgical wound healing is a complex, multistage process involving coordinated cellular and molecular events. Mechanotransduction serves as a pivotal regulatory mechanism during tissue repair, enabling cells to sense and respond to mechanical cues in the wound environment. Proper mechanotransduction orchestrates cell migration, proliferation, extracellular matrix (ECM) remodeling, and angiogenesis. Conversely, its failure disrupts these processes, predisposing wounds to dehiscence, fibrosis, or chronicity. Understanding the clinical implications of mechanotransduction failure is increasingly relevant as surgical procedures become more sophisticated and patient populations present with higher comorbid burdens. This review provides clinicians and researchers with a comprehensive, evidence-based update on mechanotransduction failure during surgical wound remodeling.

Epidemiology / Disease Burden

Non-healing surgical wounds represent a significant source of morbidity, prolonged hospitalization, and healthcare expenditure worldwide. The incidence of impaired wound remodeling, often attributable in part to mechanotransduction failure, is rising with an aging population and increased prevalence of risk factors such as diabetes, obesity, and vascular disease. Estimates suggest that up to 20% of surgical wounds develop healing complications, with mechanotransduction defects implicated in a substantial proportion. Chronic wounds, including those with pathologic remodeling, affect approximately 2% of the population in developed countries, underscoring the clinical and economic burden.

Pathophysiology

Mechanotransduction involves a cascade of signaling pathways initiated by mechanical forces acting on cells. Key mediators include integrins, focal adhesion complexes, ion channels, and the cytoskeleton, all of which link extracellular mechanical cues to intracellular responses. During wound healing, fibroblasts, keratinocytes, and endothelial cells rely on mechanotransduction to regulate proliferation, differentiation, and ECM synthesis. Failure occurs when these pathways are disrupted—due to altered mechanical loading, ECM disorganization, or molecular defects—leading to aberrant cell behavior, reduced collagen alignment, impaired granulation tissue formation, and defective angiogenesis. Recent studies highlight the role of YAP/TAZ transcriptional coactivators and mechanosensitive ion channels (e.g., Piezo1) in these processes. Dysregulation of TGF-β signaling, excessive or insufficient mechanical stress, and matrix stiffness abnormalities further compound mechanotransduction failure, culminating in poor wound remodeling.

Risk Factors

Patient-specific factors such as advanced age, diabetes mellitus, peripheral vascular disease, immunosuppression, malnutrition, and smoking compromise mechanotransduction by impairing cellular responsiveness and ECM integrity. Surgical site-related factors—such as high-tension closures, excessive tissue trauma, and infection—disrupt the mechanical microenvironment necessary for effective signal transduction. Systemic factors, including corticosteroid therapy and chemotherapy, further inhibit the cellular machinery involved in mechanotransduction. Genetic polymorphisms affecting mechanosensitive molecules (e.g., integrins, matrix proteins) are an emerging area of research, potentially predisposing certain individuals to remodeling failure.

Clinical Features

Mechanotransduction failure presents with a spectrum of clinical findings, ranging from delayed epithelialization and persistent wound drainage to frank dehiscence, hypertrophic scarring, or chronic ulceration. Wounds may exhibit poor granulation tissue, excessive fibrosis, or abnormal contracture. Patients often report prolonged healing times and may develop secondary infections or sinus tract formation. In some cases, mechanical failure manifests as incisional hernia or wound evisceration, particularly following abdominal or thoracic surgeries. Recognition of these features is critical for timely intervention.

Diagnosis

Diagnosis of mechanotransduction failure is primarily clinical, supported by a thorough assessment of wound appearance, healing trajectory, and risk factor profile. Advanced diagnostic modalities include ultrasound elastography to assess tissue stiffness, histopathological examination for ECM organization, and immunohistochemistry to detect aberrant expression of mechanosensitive proteins. Molecular assays targeting mechanotransduction pathway components (e.g., YAP/TAZ, integrins) are under investigation but not yet routine. Identification of underlying contributing factors—such as infection, ischemia, or systemic disease—is essential to guide management.

Treatment & Management

Optimal management of mechanotransduction failure involves a multifaceted approach. Surgical techniques minimizing tissue trauma and tension, utilization of tension-reducing sutures, and advanced wound closure devices (e.g., negative pressure wound therapy) help restore mechanical balance. Local wound care with dressings that modulate mechanical forces, promote moisture balance, and support ECM remodeling is beneficial. Adjunctive therapies include topical growth factors, cellular therapies (e.g., fibroblast or stem cell transplantation), and agents that enhance mechanosensitive signaling. Systemic optimization—glycemic control, nutritional support, cessation of smoking, and management of comorbidities—improves cellular responsiveness. Early identification and correction of infection or ischemia are imperative for successful outcomes.

Recent Advances / Emerging Therapies

Recent research has focused on biomaterials and scaffolds engineered to mimic physiological mechanical properties, thereby promoting mechanotransduction and tissue regeneration. Investigational agents targeting YAP/TAZ signaling or mechanosensitive ion channels are under preclinical and early clinical evaluation. Gene therapy approaches aimed at restoring or enhancing expression of key mechanotransduction molecules have demonstrated promise in animal models. Advances in regenerative medicine, including the application of mechanically-conditioned stem cells and extracellular vesicles, offer new possibilities for enhancing wound remodeling and overcoming mechanotransduction failure. Integration of real-time biomechanical monitoring and personalized wound care strategies represents a frontier in surgical wound management.

Guideline Recommendations

Recent clinical guidelines emphasize the importance of minimizing mechanical stress at the wound site, optimizing systemic health, and employing evidence-based wound care protocols. The use of tension-reducing closure techniques, advanced dressings, and negative pressure wound therapy is supported, particularly for high-risk wounds. Multidisciplinary evaluation and individualized care plans are recommended for patients with impaired healing. Ongoing research into mechanotransduction-targeted therapies is encouraged, with the goal of incorporating novel interventions into standard practice as evidence matures.

Conclusion

Mechanotransduction failure represents a pivotal pathophysiological mechanism underlying impaired surgical wound remodeling. Advances in molecular understanding and clinical management have improved recognition and outcomes, but challenges remain in translating mechanistic insights into routine practice. Continued research, early identification of at-risk patients, and integration of emerging therapies will be essential for optimizing wound healing and reducing the burden of non-healing surgical wounds among diverse patient populations.